<DOC>
	<DOCNO>NCT03005860</DOCNO>
	<brief_summary>Surgery , perioperative stress , anaesthetic analgesic may modulate immunosurveillance mechanism overwhelm host defence normally maintain balance immunity &amp; carcinogenesis . This may lead escape cancer cell tilt scale toward protumorigenic microenvironment . Volatile agent , particular , show exhibit profound immunosuppressive effect . In comparison , propofol favorable profile inhibits cancer cell activity . Determining `` cancer-protective '' role TIVA propofol present excite window opportunity potential improve outcome cancer patient undergo resection surgery</brief_summary>
	<brief_title>Effect TIVA Propofol v Sevoflurane Anaesthetic Serum Biomarkers PBMCs Breast Cancer Surgery</brief_title>
	<detailed_description>For current study , consent patient plan upfront surgery , randomly allocate 2 groups- 20 patient group : Propofol TCI-based Total Intravenous Anesthesia group ( Propofol group ) Sevoflurane group ( Sevoflurane group ) , accord computer generate randomization number . Patients monitor routinely ECG , non invasive blood pressure , pulse- oximetery ( SPO2 ) , every 5 min . An intravenous access establish 20- 22 G cannula . A perioperative antibiotic prophylaxis give patient . None patient receive premedication . After preoxygenation 100 % O2 3 min : group specific separate intervention perform . Patient ventilate TV 6-8ml/kg , respiratory rate adjust maintain end-tidal CO2 value 40 - 45 mmHg . Crystalloids use hydration ( 4-6 ml/kg/h ) , intraoperative volume deficit replace additional administration solution accord clinical need . For TIVA group , depth anaesthesia monitor use Bispectral Index , target BIS value 40 60 . For Sevoflurane group , depth anaesthesia monitor use MAC , target MAC value 0.8 1 . Half hour conclusion surgery , patient receive 0.1mg/kg ondansetron prophylaxis PONV . At end surgery , muscle relaxation reverse glycopyrrolate ( 10mcg/kg ) neostigmine ( 50mcg/kg ) . Patients group receive intra-venous non-steroidal anti-inflammatory drug 1-1.5mg/kg diclofenac + Paracetamol 1gm conclusion surgery postoperative analgesia . Postoperative pain &amp; PONV manage per institutional protocol . ASSAY Peripheral blood ( 5ml ) collect patient EDTA vaccutainer ( 5ml ) another vaccutainer contain clot activator . The sample collect following time point . 1. anaesthesia ( Tpre ) 2. removal tumor intraoperative ( Ti ) 3 . 2 h surgery ( T2h ) , 4 . ( T24h ) 24 hour surgery Estimation serum cytokine : sandwich ELISA cytokine bead array ( CBA ) method . Expression various lymphocyte subset ( CD3+ T cell , CD4+ helper T cell , CD8+ cytotoxic T cell , γδT cell , NK cell B cell ) flow cytometry</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<mesh_term>Ether</mesh_term>
	<mesh_term>Sevoflurane</mesh_term>
	<mesh_term>Atracurium</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1 . Women histopathologically ( biopsy/FNAC ) proven breast carcinoma Resectable disease ( T 14 , N 01 , M 0 ) [ Stage IIII ] . 2 . Willing upfront modified radical mastectomy . 3 . ASA Physical Status 12 1. use morphine steroid therapy upto 3 month surgery ; 2. history substance abuse cognitive dysfunction ; 3. endocrine disorder diabetes , hypothyroid ; 4. history HIV , HepB HepC infection ; 5 . Contraindication analgesic anaesthetic drug ; 6 . Pregnant &amp; lactate woman</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>